Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,392,610
-
Number of holders
-
93
-
Total 13F shares, excl. options
-
44,151,028
-
Shares change
-
+2,254,262
-
Total reported value, excl. options
-
$516,569,184
-
Value change
-
+$24,151,309
-
Put/Call ratio
-
9.4%
-
Number of buys
-
60
-
Number of sells
-
25
-
Price
-
$11.70
Institutional Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) as of Q2 2024
As of 30 Jun 2024 Mineralys Therapeutics, Inc. - Common Stock (MLYS) had 93 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 44,151,028 shares of stock of the company.
Largest 10 holders included Catalys Pacific, LLC, Samsara BioCapital, LLC, RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management, LLC, BlackRock Inc., ORBIMED ADVISORS LLC, SR One Capital Management, LP, ADAMS STREET PARTNERS LLC, FRANKLIN RESOURCES INC, and Laurion Capital Management LP.
This table shows 93 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.